Cargando…

Abnormal IGF-Binding Protein Profile in the Bone Marrow of Multiple Myeloma Patients

Insulin-like growth factor (IGF) signalling plays a key role in homing, progression, and treatment resistance in multiple myeloma (MM). In the extracellular environment, the majority of IGF molecules are bound to one of six IGF-binding proteins (IGFBP1-6), leaving a minor fraction of total IGF free...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bieghs, Liesbeth, Brohus, Malene, Kristensen, Ida B., Abildgaard, Niels, Bøgsted, Martin, Johnsen, Hans E., Conover, Cheryl A., De Bruyne, Elke, Vanderkerken, Karin, Overgaard, Michael T., Nyegaard, Mette
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4844248/ https://www.ncbi.nlm.nih.gov/pubmed/27111220 http://dx.doi.org/10.1371/journal.pone.0154256

Ejemplares similares

The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential
por: Bieghs, Liesbeth, et al.
Publicado: (2016)

The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic
por: Bieghs, Liesbeth, et al.
Publicado: (2014)

The Effects of Forodesine in Murine and Human Multiple Myeloma Cells
por: Bieghs, Liesbeth, et al.
Publicado: (2010)

Human Calmodulin Mutations
por: Jensen, Helene H., et al.
Publicado: (2018)

Calmodulin mutations affecting Gly114 impair binding to the Na(V)1.5 IQ-domain
por: Brohus, Malene, et al.
Publicado: (2023)

The Insulin-Like Growth Factor System in the Long-Lived Naked Mole-Rat
por: Brohus, Malene, et al.
Publicado: (2015)

Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma
por: Wang, Jinheng, et al.
Publicado: (2016)

Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma
por: Oudaert, Inge, et al.
Publicado: (2022)

The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells
por: Wang, Jinheng, et al.
Publicado: (2015)

Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models
por: Hu, Jinsong, et al.
Publicado: (2012)

Novel strategies to target the ubiquitin proteasome system in multiple myeloma
por: Lub, Susanne, et al.
Publicado: (2015)

Human calmodulin mutations cause arrhythmia and affect neuronal function in C. elegans
por: Jensen, Helene H, et al.
Publicado: (2023)

Hypothyroidism in hibernating brown bears
por: Frøbert, Anne Mette, et al.
Publicado: (2023)

Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma
por: Maes, Ken, et al.
Publicado: (2013)

Exposure time independent summary statistics for assessment of drug dependent cell line growth inhibition
por: Falgreen, Steffen, et al.
Publicado: (2014)

The genetic landscape of 5T models for multiple myeloma
por: Maes, Ken, et al.
Publicado: (2018)

The Use of Murine Models for Studying Mechanistic Insights of Genomic Instability in Multiple Myeloma
por: Vlummens, Philip, et al.
Publicado: (2019)

AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma
por: Yan, Siyang, et al.
Publicado: (2019)

The Epigenome in Multiple Myeloma: Impact on Tumor Cell Plasticity and Drug Response
por: De Smedt, Eva, et al.
Publicado: (2018)

Plasma proteomics data from hibernating and active Scandinavian brown bears
por: Frøbert, Anne Mette, et al.
Publicado: (2022)

Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?
por: Muylaert, Catharina, et al.
Publicado: (2022)

Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects
por: De Beck, Lien, et al.
Publicado: (2018)

Characterization and comparison of recombinant full‐length ursine and human sex hormone‐binding globulin
por: Frøbert, Anne Mette, et al.
Publicado: (2021)

The International Calmodulinopathy Registry: recording the diverse phenotypic spectrum of un-CALM hearts
por: Nyegaard, Mette, et al.
Publicado: (2019)

Ca(2+)-dependent calmodulin binding to cardiac ryanodine receptor (RyR2) calmodulin-binding domains
por: Brohus, Malene, et al.
Publicado: (2019)

The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma
por: Maes, Ken, et al.
Publicado: (2014)

Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions
por: Verheye, Emma, et al.
Publicado: (2022)

Chemerin is elevated in multiple myeloma patients and is expressed by stromal cells and pre-adipocytes
por: Westhrin, Marita, et al.
Publicado: (2018)

Cancer Associated Fibroblasts and Tumor Growth: Focus on Multiple Myeloma
por: De Veirman, Kim, et al.
Publicado: (2014)

In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma
por: Maes, Ken, et al.
Publicado: (2014)

Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models
por: Falgreen, Steffen, et al.
Publicado: (2015)

A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma
por: Nylund, Patrick, et al.
Publicado: (2021)

The Transfer of Sphingomyelinase Contributes to Drug Resistance in Multiple Myeloma
por: Faict, Sylvia, et al.
Publicado: (2019)

Exosomes play a role in multiple myeloma bone disease and tumor development by targeting osteoclasts and osteoblasts
por: Faict, Sylvia, et al.
Publicado: (2018)

Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis
por: Oudaert, Inge, et al.
Publicado: (2022)

Metabolic Features of Multiple Myeloma
por: El Arfani, Chaima, et al.
Publicado: (2018)

Inhibition of the Protein Arginine Methyltransferase PRMT5 in High-Risk Multiple Myeloma as a Novel Treatment Approach
por: Vlummens, Philip, et al.
Publicado: (2022)

PB1973: INHIBITION OF LACTATE EXPORTERS INDUCES DIRECT ANTI-TUMOR EFFECTS AND COUNTERS IMMUNE SUPPRESSION IN MULTIPLE MYELOMA
por: Van der Vreken, A., et al.
Publicado: (2022)

Proof of the Concept to Use a Malignant B Cell Line Drug Screen Strategy for Identification and Weight of Melphalan Resistance Genes in Multiple Myeloma
por: Bøgsted, Martin, et al.
Publicado: (2013)

Serum galectin-1 in patients with multiple myeloma: associations with survival, angiogenesis, and biomarkers of macrophage activation
por: Andersen, Morten Nørgaard, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_n7mnp2ubst0buoggsg5hq2n44a